7:01AM Incyte: FDA accepts NDA filing for Ruxolitinib as a treatment for Myelofibrosis (INCY) 16.24 : Co announced FDA has accepted for filing the New Drug Application for Incyte's lead investigational compound, ruxolitinib, as a potential treatment for patients with myelofibrosis. The FDA also has granted Incyte's request for Priority Review, which is given to investigational drugs that may offer either a major advance in treatment or provide a treatment where no adequate therapy exists. If the application is approved, Co anticipates that ruxolitinib could be available for US patients with MF in the fourth quarter of 2011.
Market Data 
Markets 
AI
